News Sentiment

ORKA sentiment intelligence

Oruka Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 92.70 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+6.8% over one week, +28.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 6.8% Price confirming higher
Trend fit Trend active 28.1% over four weeks
Fair value 275.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
GlobeNewswire 6
MT Newswires 4
simplywall.st 3
BizWest 3
Quiver Quantitative 2
Investing.com 2
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 25
Deals and strategy 13
Earnings 11
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
GlobeNewswire Direct company coverage

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

Oruka Therapeutics announced the completion of its merger with ARCA biopharma, Inc., and a $275 million private placement. The combined company will trade on Nasdaq under the ticker symbol "ORKA", with Samarth Kulkarni appointed Chairman of the Board. Oruka aims to advance its co

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Sep 2024 07:00
Source
GlobeNewswire
BizWest Direct company coverage

Arca Biopharma, Oruka Therapeutics merger complete

Arca Biopharma has announced the completion of its merger with Oruka Therapeutics Inc. This development follows a board approval for a 1-for-12 reverse stock split by Arca Biopharma prior to the merger. The article also touches upon related news in the biopharmaceutical sector, i

Tone
Positive 67/100
Event
Deals and strategy
Published
30 Aug 2024 12:36
Source
BizWest
GlobeNewswire Direct company coverage

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma has announced the completion of its merger with Oruka Therapeutics and the implementation of a 1-for-12 reverse stock split. The combined entity will operate as Oruka Therapeutics, Inc., with its common stock trading on Nasdaq under the symbol "ORKA" starting Septe

Tone
Positive 72/100
Event
Deals and strategy
Published
29 Aug 2024 16:50
Source
GlobeNewswire
BizWest Direct company coverage

Arca Biopharma board approves reverse stock split prior to Oruka merger

Arca Biopharma's board of directors has approved a 1-for-12 reverse stock split. This action is being taken in advance of the drug-discovery company's upcoming merger with Oruka Therapeutics Inc. The full article content is for subscribers only.

Tone
Neutral 50/100
Event
Deals and strategy
Published
26 Aug 2024 18:41
Source
BizWest
GlobeNewswire Direct company coverage

ARCA biopharma Provides Update Regarding Special Dividend

ARCA biopharma announced an updated special cash dividend of $1.613 per share, payable on August 28, 2024, to stockholders of record as of August 26, 2024, in connection with its upcoming merger with Oruka Therapeutics. Due to the dividend's size, Nasdaq has set August 29, 2024,

Tone
Neutral 50/100
Event
Capital return
Published
26 Aug 2024 01:52
Source
GlobeNewswire
Market source Direct company coverage

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma announced a 1-for-12 reverse stock split ahead of its merger with Oruka Therapeutics, effective September 3, 2024. Following the merger, ARCA will trade as Oruka Therapeutics, Inc. under the new ticker symbol "ORKA". The split will reduce outstanding shares and adj

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Aug 2024 04:23
Source
Market source
BizWest Direct company coverage

Arca Biopharma plans to sell off tech, IP as part of Oruka merger

Arca Biopharma Inc. intends to divest assets related to its drug-discovery technology and intellectual property. This divestiture is a component of its anticipated reverse merger with Oruka Therapeutics Inc. The article is subscriber-only, limiting further details.

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Aug 2024 11:09
Source
BizWest
FinancialContent Direct company coverage

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Kahn Swick & Foti, LLC, led by former Attorney General Charles C. Foti, Jr., is investigating the proposed merger of ARCA biopharma, Inc. (ABIO) and Oruka Therapeutics. The investigation aims to determine if the merger is fair to ARCA shareholders, who are expected to own only 2.

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 May 2024 18:34
Source
FinancialContent
Market source Direct company coverage

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

ARCA biopharma and Oruka Therapeutics have announced a definitive merger agreement in an all-stock transaction. The combined company, to be named Oruka Therapeutics, Inc., will focus on advancing Oruka's biologics pipeline for chronic skin diseases, including ORKA-001 and ORKA-00

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Apr 2024 15:09
Source
Market source
Invezz Direct company coverage

Arca Biopharma stock ($ABIO) soars on merger news

Arca Biopharma's stock surged after announcing a reverse merger with Oruka Therapeutics. The combined entity will operate as Oruka Therapeutics and secured $275 million in private financing to fund operations through 2027. This merger aims to advance Oruka's therapies for chronic

Tone
Positive 87/100
Event
Deals and strategy
Published
03 Apr 2024 11:38
Source
Invezz
Market source Direct company coverage

Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details

ARCA Biopharma Inc. (NASDAQ: ABIO) is merging with Oruka Therapeutics, a private biotechnology company, in an all-stock transaction. The combined entity, to be named Oruka Therapeutics Inc. and trade under "ORKA," will focus on advancing Oruka’s pipeline for chronic skin diseases

Tone
Positive 70/100
Event
Deals and strategy
Published
03 Apr 2024 09:09
Source
Market source
STAT Direct company coverage

Investors funnel $275 million into Paragon Therapeutics-spinout

Investors have committed $275 million to Oruka Therapeutics, a new biotech company specializing in treatments for psoriasis and psoriatic arthritis that could be administered as infrequently as once or twice a year. Oruka Therapeutics was launched through a reverse merger with AR

Tone
Positive 72/100
Event
Deals and strategy
Published
03 Apr 2024 04:23
Source
STAT